Mundipharma EDO GmbH shows strong preclinical activity with lead compound (EDO-S101) in multiple myeloma

Mundipharma EDO GmbH (Early Development in Oncology) is pleased to announce strong preclinical activity in Multiple Myeloma with its lead small molecule compound EDO-S101, presented at the European Haematology Association in Milan in June 2014.

Source: Pharmacy Europe - July 15, 2014 Category: Drugs & Pharmacology Authors: ebercott Tags: *** Editor's Pick Oncology Latest News Source Type: news